Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Eyes Clear Opportunity to Bring Impactful Therapy to GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system. Over recent months, the company has achieved several milestones demonstrating its operational, financial and strategic strengths and continuous de-risking of its lead candidate Berubicin clinical program. “The company has begun a pivotal Phase 2 clinical trial evaluating the efficacy and safety of Berubicin for recurrent adult glioblastoma multiforme (‘GBM’). Enrollment in the clinical trial is already underway, with patient dosing set to begin in Q3 2021,” reports an article discussing the status of the study to treat GBM, an aggressive type of brain cancer with most treatments only slowing progression and reducing symptoms. “Berubicin is a novel therapy for GBM and the first anthracycline to cross the blood-brain barrier and kill cancerous tumor cells in humans. The Phase 1 safety trial for Berubicin was conducted by another company 14 years ago. Since then, one patient has lived cancer-free, with two others seeing a reduction in tumor size by up to 80%. . . . With the serious unmet medical need for new GBM treatments, CNS Pharmaceuticals applied for and was granted FDA Fast Track Designation for Berubicin. According to CNS Pharmaceuticals CEO John Climaco, receiving Fast Track Designation is a major achievement for the advancement of Berubicin for the treatment of the most aggressive, deadly and treatment-resistant type of brain cancer. ‘Patients have almost no meaningful options and thousands lose their fight against this terrible cancer every year. With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,’ he explained.”

To view the full article, visit https://ibn.fm/avK4x

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – Nextech AR Solutions Corp. (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29) to Release Q2 2021 Earnings, Schedules Earnings Call

Nextech AR Solutions (OTCQB: NEXCF) (NEO: NTAR) (CSE: NTAR) (FSE: N29), a diversified leading provider of augmented reality (“AR”) solutions and services, has announced plans to release its second-quarter 2021 financial results on Aug. 11, 2021, after markets close. The company will also host a conference call to discuss its financial numbers and results on Aug. 12 , 2021, at 1 p.m. ET. Nextech CEO Evan Gappelberg and CFO Andrew Chan will host the call and provide an overview of company financial and operating results; the call will also include a question-and-answer period. Interested individuals can call in toll-free by dialing (877) 201-0168 — (647) 788-4901 for international callers — and using the conference ID 2086367. The call is also available in webcast format. A recording of the presentation will be available on the company’s website following the conclusion of the call.

To view the webcast event, visit https://ibn.fm/sU5mD

To view the full press release, visit https://ibn.fm/nS0fT

About Nextech AR Solutions Corp.

Nextech develops and operates augmented reality (“AR”) platforms that transport three-dimensional (“3D”) product visualizations, human holograms and 360-degree portals to its audiences altering e-commerce, digital advertising, hybrid virtual events (events held in a digital format blended with in-person attendance) and learning and training experiences.

Nextech focuses on developing AR solutions; however, most of the company’s revenues are derived from three e-commerce platforms: vacuumcleanermarket.com (“VCM”), infinitepetlife.com (“IPL”) and Trulyfesupplements.com (“TruLyfe”). VCM and product sales of residential vacuums, supplies and parts, and small home appliances sold on Amazon. For more information about the company, please visit www.NextechAR.com.    

NOTE TO INVESTORS: The latest news and updates relating to NEXCF are available in the company’s newsroom at https://ibn.fm/NEXCF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Nextech AR Solutions Corp. NEXCF | Leave a comment

MissionIRNewsBreaks – Excellon Resources Inc. (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) Announces Progress of Silver City Drilling Program

Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) today provided an update on the ongoing drilling program at the Silver City Project located in Saxony, Germany. Among the highlights, the company reported smooth commencement of drilling at the first of four priority targets of the 12,000-metre diamond drilling program planned for 2021. In addition, a second drill rig was added to the program, with drilling now underway at the Peter Vein (Neue Hoffnung Gottes) and Bräunsdorf (Christbescherung) targets. “We have had another smooth startup of drilling at Silver City this year,” said Ben Pullinger, SVP Geology & Corporate Development. “We continue to appreciate the support of the local community and benefit from the excellent work of the TU Bergakademie Freiberg and the Helmholtz Institute of Freiberg. This year’s program builds on discoveries made last year in the first modern-day drilling for precious metals on the Bräunsdorf license. Our current drilling focusses on the historically productive gneiss-schist contact running through the Bräunsdorf and Peter Vein mines. In the coming weeks we will move up to the mafic-schist contact intersected last year at Reichenbach and Grauer Wolf, both of which yielded some of the most interesting results from drilling to date.”

To view the full press release, visit https://ibn.fm/5OtDG

About Excellon Resources Inc.

Excellon’s vision is to create wealth by realizing strategic opportunities through discipline and innovation for the benefit of its employees, communities and shareholders. The company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration. The company also aims to continue capitalizing on current market conditions by acquiring undervalued projects. Additional details on Excellon’s properties are available at www.ExcellonResources.com.

NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at https://ibn.fm/EXN     

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Excellon Resources Inc. EXN | Leave a comment

MissionIRNewsBreaks – XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Acquisition Target Identifies Breakthrough COVID-19 Detection Biosensor Candidates

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a life sciences technology accelerator, today announced that its acquisition target, 3a-diagnostics GmbH (“3a”), has identified the first saliva activated “in-mouth” biosensor candidates for the detection of a COVID-19 infection. According to the update, the enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at home or at the point-of-care. “We believed in 3a’s research and development plan from the beginning, when we signed the first collaboration contract in 2020. Now that XPhyto has announced the pending acquisition of 3a, we are particularly excited about this development milestone,” said Wolfgang Probst, director and COO of XPhyto. “Successful validation of the first biosensor candidates demonstrates the expertise and scientific excellence at 3a. Since the co-developed and successfully approved German CE marked 25-minute PCR test in March of this year, this novel approach for oral biosensor screening is another important milestone towards development of tools to effectively identify infectious breakouts of COVID-19 to reduce the pandemic spread and help find our way back to the new normal.”

To view the full press release, visit https://ibn.fm/obT8M 

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.Xphyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, XPhyto Therapeutics Corp. XPHYF | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reaches Milestone in Human Clinical Study, Notes Growing Availability of DehydraTECH-Enabled Products

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reached a significant point in its second human clinical study of 2021: HYPER-H21-2. The company announced that dosing has been completed in the study, which was comprised of 16 human volunteers who were pre- or mildly hypertensive; each participant received three separate doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo. The study also included 24-hour continuous monitoring of blood pressure and heart rate, as well as evaluations of central arterial stiffness, physical activity and sleep quality. This key information will be assessed to evaluate the human response to DehydraTECH 2.0-enabled CBD. The company anticipates beginning a third human clinical study, HYPER-H21-3, following analysis of results from the first and second studies. In addition, Lexaria announced the expansion of its intellectual property portfolio with the allowance of its second patent in Japan. The patent is the 21st patent the company has been granted. Lexaria also noted that more than 7,000 stores across the country sell products that use its exclusive DehydraTECH technology. Some of those products include Cannadips, the original tobacco-free and nicotine-free CBD pouch; a growing number of New World CBD SKUs; and next-generation CHYLOSOMA(TM) formulations of CBD, CBG and CBN topical skin offerings. “Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” said Lexaria CEO Chris Bunka. “We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come.”

To view the full press releases, visit https://ibn.fm/VRWlO and https://ibn.fm/b4g0z

About Lexaria Bioscience Corp.

Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit http://www.LexariaBioScience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment

MissionIRNewsBreaks – Net Element Inc. (NASDAQ: NETE) Updates Shareholders, Announces Registration Statement for Proposed Merger Declared Effective by SEC

Net Element (NASDAQ: NETE), a financial technology company in the process of becoming a pure-play electric vehicle (“EV”) manufacturer through a pending definitive agreement with privately held Mullen Automotive Inc., has shared key updates with shareholders. Earlier this year, the company purchased more than 100 acres along with a 120,000-square-foot facility, which will become the company’s Advanced Engineering and Manufacturing Center and Proving Grounds (“AMEC”); the property is located in Tunica, Mississippi. The company intends to construct a 700,000-square-foot body shop, paint shop, warehouse and test track to complete an automotive campus with more than 820,000 square feet of building space and the capacity to produce an estimated 100,000 vehicles annually. The company has also hired key personnel, including Trey Agner as director of operations and Jerry Baker as production manager; the two will oversee work on the AMEC campus. The company also noted that Mullen has been fine-tuning the design, material selections and vehicle build for its  FIVE Crossover EV, which will be unveiled later this year. In addition, NETE has been notified that the registration statement on Form S-4 (File No. 333-256166) was declared effective by the U.S. Securities and Exchange Commission (“SEC”). The statement is concerning NETE’s proposed merger with Mullen, a privately held EV company based in Southern California. The next step forward for the planned merger will be the Special Meeting of Net Element stockholders, scheduled for Aug. 26, 2021, at 11 a.m. ET. “I’m very grateful for all the hard work the Mullen team has put into filing the recently cleared S4, which represents a significant milestone in merging with Net Element,” said Mullen CEO and chair David Michery in the press release. “I look forward to a successful transition with NETE and congratulate their team for making this happen. Our focus continues on our EV efforts, and we are looking forward to debuting our first EV crossover, the Mullen FIVE.”

To view the full press releases, visit https://ibn.fm/4iHjE and https://ibn.fm/0twMF

About Net Element Inc.

Net Element operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the United States and selected emerging markets. In the United States, the company aims to grow transactional revenue by innovating SME productivity services using blockchain technology solutions and Aptito, its cloud-based, restaurant and retail point-of-sale solution. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest-growing companies in North America on Deloitte’s 2017 Technology Fast 500(TM) and by “South Florida Business Journal” as one of 2016’s fastest-growing technology companies. For additional information about the company, visit www.NetElement.com.

NOTE TO INVESTORS: The latest news and updates relating to NETE are available in the company’s newsroom at http://ibn.fm/NETE

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Net Element Inc. NETE | Leave a comment

MissionIRNewsBreaks – Kaival Brands Innovations Group Inc. (KAVLD) Announces Approval to Trade on Nasdaq Exchange

Kaival Brands (OTCQB: KAVLD), the exclusive global distributor of products manufactured by Bidi(R) Vapor LLC, has received approval from the Nasdaq Stock Market LLC to list the company’s common stock on the Nasdaq Market; the listing will be effective beginning Thursday, July 29, 2021. The announcement noted that the company’s ticker symbol, KAVL, will remain unchanged. The announcement noted that Bidi Vapor’s founding mission is to provide recreational, noncombusted alternatives for adult cigarette smokers including the BIDI(R) Stick and the BIDI(R) Pouch. “I am pleased to announce that the company has been approved to begin trading on Nasdaq,” said Kaival Brands founder and CEO Niraj Patel in the press release. “This event represents another monumental milestone in our company’s short history. We have worked diligently to achieve this goal and are humbled and grateful on the inclusion to the Nasdaq. We are more enthusiastic than ever about being able to harness Kaival’s exciting potential.”

To view the full press releases, visit https://ibn.fm/cHu6j

About Kaival Brands Innovations Group Inc.

Based in Grant, Florida, Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVLD are available in the company’s newsroom at http://ibn.fm/KAVL

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Kaival Brands Innovations Group Inc. KAVLD, MissionIRNewsBreaks | Leave a comment

Heavy Hurricane Forecast Portends Busy Season for Sustainable Green Team Ltd. (SGTM)

  • Some estimate the U.S. will run out of landfill space within 15 years
  • This year’s hurricane season expected to have above average activity
  • SGTM, through its subsidiaries, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging, sales

This month, the world watched as Hurricane Elsa made landfall in Cuba on July 5, tore through Jacksonville, Florida days later and then proceed to wreak havoc up the East Coast and into Atlantic Canada (https://ibn.fm/uN9tu). Indeed, the latest iteration of hurricane season is upon us, and it’s expected to be an above average year for activity, which has cities scrambling to fill public works jobs and Sustainable Green Team (OTC: SGTM) readying its crews for months of debris removal (https://ibn.fm/QFILQ).

Officially, the Atlantic hurricane season, which covers the Atlantic Ocean, Gulf of Mexico and the Caribbean Sea, runs from June 1 – November 30. By definition, Elsa, the first of the year, was only a Category 1 hurricane, but it certainly demonstrated the raw power of torrential winds and rain that downed countless trees and left over 100,000 without power in its wake, including over 85,000 in New Jersey alone (https://ibn.fm/EjbBy).

Sustainable Green Team, Ltd., through its subsidiaries, including National Storm Recovery LLC, provides tree services, debris hauling and removal, biomass recycling, mulch manufacturing, packaging and sales. The Delaware-based company was established with the objective of providing a solution for the treatment and handling of tree debris that has historically been disposed of in landfills, creating an environmental burden and pressure on disposal sites around the nation.

To understand the importance of Sustainable Green Team’s work, consider that SWEEP (Solid Waste Environmental Excellence Performance) contests that the U.S. is charting a course to run out of landfill space in the next 15 years (https://ibn.fm/DIvZS). Environmentalists also warn that uncaptured methane gas from landfills was the third biggest contributor to human-related methane emissions in the U.S. in 2018, with the equivalency to carbon dioxide emissions from 20.6 million passenger vehicles driven for one year (https://ibn.fm/esAPI).

Sustainable Green Team’s solutions are rooted in sustainability and based on vertically integrated operations. In the event of a storm, SGTM’s team is deployed from a mobile command center to designated sites to strategize with national partners comprised of government agencies, prime contractors, and subcontractors.

Next, its tree services division and fleet of trucks and machinery cut and gather tree debris for collection sites. From there, the processing division takes over, using the tree debris as feedstock that is turned into a variety of organic, next-generation mulch products that are subsequently sold to landscapers, installers and garden centers. 

In short, a downed tree isn’t used for another layer in a landfill; it’s recycled into a premium product for SGTM’s municipal, commercial, and residential customers. Better still, it helps in the efforts to prevent deforestation.

The company is far removed from a typical OTC company. It has six different production facilities covering hundreds of acres in Florida and Georgia. It also has seven co-packing partners, 23 distribution centers, eight intermodal ramps, and direct contracts with CSX and Norfolk Southern to move product by rail. In 2020, SGTM acquired Ohio-based Mulch Manufacturing, widening its national footprint and adding contracts for bagged mulch with big box stores to its revenue stream. 

To that point, SGTM has parlayed it environmentally friendly processes into growing sales. The Company reported record revenue of $9.29 million, $1.4 million in gross profit and $41.48 million in total assets for the quarter ended April 30, 2021.

No one likes to hear about a hurricane or the see the devastation one leaves behind. Unfortunately, it makes for good news reports for a few days, but then the cameras disappear, and communities are left to pick up the pieces. Thankfully, a company like SGTM is there with the complete infrastructure to assist in the eco-friendly manner to see that the environmental damage doesn’t have to be any more than it already is.

For more information on Sustainable Green Team Management, visit www.CentralFloridaArborcare.com

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Sustainable Green Team Ltd. SGTM | Leave a comment

SRAX Inc. (NASDAQ: SRAX) Releases Suite of Tools Designed to Help Bridge Gap Between Listed Corporations and Investors

  • Registered Investment Advisors and retail investors cumulatively account for significant proportion of US equity market assets under management
  • SRAX’s Sequire platform bridges gap between corporations and their end investors
  • SRAX recently introduced automated email and SMS functions, allowing companies to efficiently communicate with millions of retail investors on their platform
  • Listed companies will also be able to search and interact with investment advisor community through Sequire’s proprietary search functions

Investment advisors make up a huge segment of the U.S. investor base; according to a recent survey carried out by RIA Channel, there were 14,955 independent registered investment advisors in the United States with cumulative assets under management of $2.969 trillion (https://ibn.fm/gkVER). Meanwhile, retail investors have increasingly become a dominant force within the U.S. equity market; a study carried out by Morgan Stanley revealed that retail investors accounted for close to 10 percent of daily trading volume on the Russell 3000, the broadest U.S. stocks index, after peaking at 15% in September 2020 as widespread lockdowns and increased savings triggered interest in the markets (https://ibn.fm/ecxI4). SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has sought to bridge the gap between listed corporations and the two investor sub-sets through the introduction of a number of novel features on its platform.  

As of May 2021, SRAX revealed that its Sequire platform had seen its corporate subscriber base swell to 183 publicly listed companies in addition to boasting a network of over five million influential, forward-thinking investors and shareholders. Sequire has recently released new features to help facilitate communication between its listed corporate subscribers and retail investor base, consisting of an automated email feature as well as an SMS function. 

Sequire’s listed corporate base will have access to custom filters to assist them in structuring campaigns directed at specific investor categories (https://ibn.fm/mmDe2), along with automation triggers, machine learning and other enhancements designed to promote frictionless communication between corporations and the millions of retail investors on their platform. 

“These new tools will allow companies to better manage communication with their shareholder base by defining pre-established triggers that will execute both email and SMS messages,” said SRAX Founder and CEO Christopher Miglino (https://ibn.fm/u0ITG).

SRAX has simultaneously released new search features, enabling companies to access contact information on registered investment advisors. Banking on the knowledge that close corporate interactions with investment advisors make it more likely that a given investment advisor will recommend a company’s stock to clients, the investment advisor feature on Sequire will seek to assist issuers in developing significant connections and ties with the investment advisor community (https://ibn.fm/0deuy).

SRAX’s corporate subscribers will be able to search and filter for specific types of advisors, designed to assist them in efficiently contacting their target audience. Moreover, in addition to assisting issuers in communicating with the advisors, the platform will also enable companies to track their subsequent participation in their listed equity. 

“Registered Investment Advisors have been the largest investors in our company SRAX and have been a significant part of the growth of our shareholder base. We are now providing the tools that will enable issuers to identify, communicate with and track the progress of specific advisors,” stated Christopher Miglino.

For more information, visit the company’s websites at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX 

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in SRAX, Inc. SRAX | Leave a comment

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy

  • Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application
  • Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates
  • Cybin is confident this added focus will better enable the evaluation of patient outcomes

Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy.

“The digital therapeutics platform, which is proprietary to Cybin and the subject of the company’s 13th patent application, adds another dimension to the company’s development programs,” the announcement said. “The aim of utilizing and leveraging cutting-edge technologies to support drug-development candidates will be a top priority as both the industry and the company evolve.”

Already a recognized leader in progressing psychedelic therapeutics, Cybin is looking to evolve its programs beyond the psychedelic molecule into an eco-system that may potentially drive improved patient treatments through the advancement of its digital therapeutics development. In a strategic approach to accomplishing this objective, the company created a patient steering committee that, as part of the Cybin innovation team, is focused on the next phase of the digital therapeutics platform.

Cybin is confident this added focus will better enable the evaluation of patient outcomes through a highly secure, patient-centered data analytics platform for better pre- and post- psychedelic treatments. Other steps the company has taken recently to strengthen its presence in the market include collaborations with Kernel and its quantitative neuroimaging technology and Greenbrook TMS, the operator of 129 outpatient mental health service centers in the United States. The company is also working to advance other proprietary tools such as the EMBARK psychotherapy model. 

These efforts are all focused on Cybin’s commitment to building an advanced eco-system that can drive innovation from the psychedelic molecule, delivery of the molecule, quantitative testing of the molecule in patients to late-stage trials and one day potential patient treatments.

Cybin operates under the principle that psychedelic therapies offer a novel approach to mental health care that is focused on treating the underlying conditions and improving the patient experience and outcome. Recognizing that a paradigm shift in public policy has opened the door to new research and development in the field of psychedelic medicine and treatment regimens, the company is at the forefront of exploring all that psychedelics offer. “We believe that psychedelic therapies will be key to addressing the mental health crisis by transforming the treatment landscape,” the company states.

Cybin Corp., a leading biotech company focused on progressing psychedelic therapeutics, is on a mission to revolutionize mental health care. The company is focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Cybin Inc. CLXPF | Leave a comment